FDA Recalls Injectable Phenylephrine Solution Due to Sterility Assurance Issue
Central Admixture Pharmacy Services is recalling 14,205 bags of injectable phenylephrine solution nationwide following FDA inspection findings regarding sterility assurance. The product is prescription-only with nationwide distribution.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable product due to lack of sterility assurance, representing significant risk to patients. No illnesses or injuries are reported in the source, meeting the criteria for High severity: a risk-of-harm product where injury has not yet been reported.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 14,205 bags of injectable phenylephrine solution nationwide. The product is phenylephrine 40 mg per 250 mL added to 0.9% sodium chloride solution (160 mcg/mL), supplied in 250 mL bags for intravenous administration, NDC 71285-6092-1.
The recall was initiated because an FDA inspection called into question the sterility of the products intended to be sterile. The affected product has been distributed nationwide.
Multiple lot numbers are affected, with expiration dates ranging from May 2023 through June 2023. The recalled lots include 37-883910 (Exp 05/02/2023), 37-884221 (Exp 05/03/2023), 37-884756 (Exp 05/05/2023), 37-885358 (Exp 05/08/2023), 37-885683 (Exp 05/09/2023), and others through 37-896923 (Exp 06/22/2023).
Healthcare providers should quarantine remaining product and contact Central Admixture Pharmacy Services or the FDA with questions about this recall.
The recalled product
- Product
- PHENYLephrine added to 0.9% sodium chloride, 40 mg/250 mL* (160 mcg/mL), 250 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-6092-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable Solution
- Affected units
- 14,205
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # 37-883910
- Exp 05/02/2023
- 37-884221
- Exp 05/03/2023
- 37-884756
- Exp 05/05/2023
- 37-885358
- Exp 05/08/2023
- 37-885683
- Exp 05/09/2023
- 37-886267
- 37-886268
- Exp 05/11/2023
- 37-886539
- Exp 05/14/2023
- 37-887458
- 37-887459
- Exp 05/16/2023
- 37-888080
- Exp 05/18/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 108 recalled by Central Admixture Pharmacy Services, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 108 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services, Inc.
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22